High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial-Reference-Cited by-同舟云学术

High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial

Published:2015-03 Issue:3 Volume:16 Page:320-327
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Zapatero Almudena,Guerrero Araceli,Maldonado Xavier,Alvarez Ana,Segundo Carmen Gonzalez San,Rodríguez Maria Angeles Cabeza,Macias Victor,Olive Agustí Pedro,Casas Francesc,Boladeras Ana,de Vidales Carmen Martín,de la Torre Maria Luisa Vazquez,Villà Salvador,de la Haza Aitor Perez,Calvo Felipe A

Funder

FIS (Spanish National Health Investigation Fund) and AstraZeneca

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? Meta-analysis of randomized trials;Bria;Cancer,2009

2. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 86-10;Roach;J Clin Oncol,2008

3. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study;Bolla;Lancet Oncol,2010

4. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer;Horwitz;J Clin Oncol,2008

5. Duration of androgen suppression in the treatment of prostate cancer;Bolla;N Engl J Med,2009

Cited by 266 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Volumetric Modulated Arc Therapy for High-Risk and Very High-Risk Locoregional Prostate Cancer in the Modern Era: Real-World Experience from an Asian Cohort;Cancers;2024-08-25

2. The extracellular matrix component perlecan/HSPG2 regulates radioresistance in prostate cancer cells;Frontiers in Cell and Developmental Biology;2024-08-01

3. Japanese clinical practice guidelines for prostate cancer 2023;International Journal of Urology;2024-07-30

4. Significance of androgen‐deprivation therapy for intermediate‐ and high‐risk prostate cancer treated with high‐dose radiotherapy: A literature review;International Journal of Urology;2024-07-17

5. Hypofractionated radiation therapy combined with androgen deprivation therapy for clinically node-positive prostate cancer;Radiation Oncology Journal;2024-06-30